Corcept Therapeutics annual ebitda
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Corcept Therapeutics EBITDA Growth & History (CORT)
Corcept Therapeutics's calculated EBITDA was $45.9M for fiscal 2025.
View full Corcept Therapeutics company overviewCorcept Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $45.9M | −$91.8M | −66.64% |
| 2024 | 2024-12-31 | $137.7M | $29.4M | +27.16% |
| 2023 | 2023-12-31 | $108.3M | −$5.6M | −4.89% |
| 2022 | 2022-12-31 | $113.9M | −$11.7M | −9.28% |
| 2021 | 2021-12-31 | $125.5M | −$3.2M | −2.47% |
| 2020 | 2020-12-31 | $128.7M | $16.4M | +14.62% |
| 2019 | 2019-12-31 | $112.3M | $22.6M | +25.16% |
| 2018 | 2018-12-31 | $89.7M | $36.8M | +69.43% |
| 2017 | 2017-12-31 | $53.0M | $42.7M | +415.89% |
| 2016 | 2016-12-31 | $10.3M | $13.6M | — |
| 2015 | 2015-12-31 | −$3.3M | $24.2M | — |
| 2014 | 2014-12-31 | −$27.5M | $13.9M | — |
| 2013 | 2013-12-31 | −$41.4M | −$5.2M | — |
| 2012 | 2012-12-31 | −$36.2M | −$3.9M | — |
| 2011 | 2011-12-31 | −$32.3M | −$4.9M | — |
| 2010 | 2010-12-31 | −$27.4M | −$7.2M | — |
| 2009 | 2009-12-31 | −$20.2M | — | — |
Corcept Therapeutics quarterly ebitda
Q3.10
Q3.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $42.2M | $15.0M | +55.33% |
| Q1 2026 | 2026-03-31 | −$49.0M | −$52.9M | — |
| Q4 2025 | 2025-12-31 | $5.0M | −$20.6M | −80.55% |
| Q3 2025 | 2025-09-30 | $10.7M | −$36.2M | −77.20% |
| Q2 2025 | 2025-06-30 | $27.1M | −$8.5M | −23.90% |
| Q1 2025 | 2025-03-31 | $3.9M | −$25.7M | −86.91% |
| Q4 2024 | 2024-12-31 | $25.5M | −$6.3M | −19.89% |
| Q3 2024 | 2024-09-30 | $46.9M | $15.5M | +49.37% |
| Q2 2024 | 2024-06-30 | $35.7M | $5.7M | +18.87% |
| Q1 2024 | 2024-03-31 | $29.6M | $14.6M | +97.14% |
| Q4 2023 | 2023-12-31 | $31.9M | $8.7M | +37.67% |
| Q3 2023 | 2023-09-30 | $31.4M | −$720,000 | −2.24% |
| Q2 2023 | 2023-06-30 | $30.0M | −$1.5M | −4.88% |
| Q1 2023 | 2023-03-31 | $15.0M | −$12.0M | −44.47% |
| Q4 2022 | 2022-12-31 | $23.2M | — | — |
| Q3 2022 | 2022-09-30 | $32.1M | — | — |
| Q2 2022 | 2022-06-30 | $31.5M | −$2.6M | −7.65% |
| Q1 2022 | 2022-03-31 | $27.1M | $7.2M | +36.02% |
| Q2 2021 | 2021-06-30 | $34.2M | −$1.2M | −3.46% |
| Q1 2021 | 2021-03-31 | $19.9M | −$18.1M | −47.58% |
| Q4 2020 | 2020-12-31 | $30.6M | −$4.7M | −13.21% |
| Q3 2020 | 2020-09-30 | $24.8M | −$8.4M | −25.32% |
| Q2 2020 | 2020-06-30 | $35.4M | $10.6M | +42.69% |
| Q1 2020 | 2020-03-31 | $37.9M | $18.9M | +99.19% |
| Q4 2019 | 2019-12-31 | $35.2M | $10.3M | +41.13% |
| Q3 2019 | 2019-09-30 | $33.2M | $10.2M | +44.24% |
| Q2 2019 | 2019-06-30 | $24.8M | $4.1M | +19.86% |
| Q1 2019 | 2019-03-31 | $19.1M | −$2.0M | −9.46% |
| Q4 2018 | 2018-12-31 | $25.0M | $3.2M | +14.84% |
| Q3 2018 | 2018-09-30 | $23.0M | $9.4M | +68.58% |
| Q2 2018 | 2018-06-30 | $20.7M | $7.9M | +61.60% |
| Q1 2018 | 2018-03-31 | $21.0M | $16.3M | +342.73% |
| Q4 2017 | 2017-12-31 | $21.7M | $16.7M | +332.99% |
| Q3 2017 | 2017-09-30 | $13.7M | $10.6M | +341.61% |
| Q2 2017 | 2017-06-30 | $12.8M | $11.3M | +735.77% |
| Q1 2017 | 2017-03-31 | $4.8M | $4.1M | +667.85% |
| Q4 2016 | 2016-12-31 | $5.0M | $3.3M | +199.11% |
| Q3 2016 | 2016-09-30 | $3.1M | $3.0M | +2243.18% |
| Q2 2016 | 2016-06-30 | $1.5M | $2.6M | — |
| Q1 2016 | 2016-03-31 | $619,000 | $4.6M | — |
| Q4 2015 | 2015-12-31 | $1.7M | $4.7M | — |
| Q3 2015 | 2015-09-30 | $132,000 | $5.2M | — |
| Q2 2015 | 2015-06-30 | −$1.1M | $5.4M | — |
| Q1 2015 | 2015-03-31 | −$4.0M | $8.8M | — |
| Q4 2014 | 2014-12-31 | −$3.0M | $7.0M | — |
| Q3 2014 | 2014-09-30 | −$5.1M | $4.7M | — |
| Q2 2014 | 2014-06-30 | −$6.5M | $4.2M | — |
| Q1 2014 | 2014-03-31 | −$12.8M | −$1.9M | — |
| Q4 2013 | 2013-12-31 | −$10.0M | −$42,000 | — |
| Q3 2013 | 2013-09-30 | −$9.7M | −$2.1M | — |
| Q2 2013 | 2013-06-30 | −$10.8M | −$3.2M | — |
| Q1 2013 | 2013-03-31 | −$10.9M | $97,000 | — |
| Q4 2012 | 2012-12-31 | −$10.0M | — | — |
| Q3 2012 | 2012-09-30 | −$7.7M | −$1.2M | — |
| Q2 2012 | 2012-06-30 | −$7.6M | — | — |
| Q1 2012 | 2012-03-31 | −$11.0M | — | — |
| Q3 2011 | 2011-09-30 | −$6.4M | $667,000 | — |
| Q3 2010 | 2010-09-30 | −$7.1M | — | — |
Corcept Therapeutics ebitda trends
Over the last five fiscal years, Corcept Therapeutics's ebitda decreased from $128.7M to $45.9M, a change of −$82.8M. The latest reported quarter, Q2 2026, shows $42.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Corcept Therapeutics source filings ↗Community posts
Corcept receives positive European recommendation for ovarian-cancer therapy
European drug advisers recommended approval of Corcept’s ($CORT) relacorilant, to be marketed as Lifyorli, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The positive opinion from the Committee for Medicinal Produ ...
